Form 4: Mirum Pharmaceuticals Director Patrick Heron Reports Stock Purchase

Director Patrick Heron reports purchasing 230 shares of Mirum Pharmaceuticals through Frazier Life Sciences X, L.P. at a weighted average price of $41.5783 on September 6, 2024.

Summary

• On September 6, 2024, Patrick J. Heron, a director of Mirum Pharmaceuticals, Inc., reported acquiring 230 shares of common stock.
• The shares were purchased at a weighted average price of $41.5783, with individual prices ranging from $41.50 to $41.67.
• The transaction was conducted through Frazier Life Sciences X, L.P., where Heron is a managing member and shares voting and dispositive power.
• Heron also indirectly owns 3,566,912 shares through Frazier Life Sciences IX, L.P.
• Heron disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, reflecting a neutral sentiment. It simply reports a transaction.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, providing transparency to the market regarding the transactions of company directors. It is common for directors to have indirect ownership through investment funds.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder confidence, as it indicates a director's investment in the company.

Key Dates